However, this study was only conducted in animal models, prospective future studies would be needed to demonstrate the safety and the efficacy of CD34+ HSCs and above all to understand the correct doses of these cells to be administered in the different age groups and also in human neonate with cerebral palsy. The gene discussed is CD34; the disease is cerebral palsy.